BAM
NMTC icon

Belpointe Asset Management’s NeuroOne Medical Technologies NMTC Stock Holding History

Belpointe Asset Management’s Portfolio NMTC Stock Details NMTC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$38K Hold
12,500
– – ﹤0.01% 1115
2026
Q1 		$58.2K Buy
+12,500
New +$60K ﹤0.01% 1054
2023
Q1 		– Sell
-114
Closed -$818 – 3811
2022
Q4 		$818 Buy
+114
New +$1.02K ﹤0.01% 3474

Other funds holding NMTC

BL
Bleichroeder LP New York $559M AUM 83.7% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BA
Bard Associates Chicago, Illinois $451M AUM 66.6% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
EIM
Essex Investment Management Boston, Massachusetts $763M AUM 108.51% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

Belpointe Asset Management's NMTC Position: Q2 2026 in Review

Belpointe Asset Management held its NeuroOne Medical Technologies (NMTC) position steady in Q2 2026 at 12,500 shares worth $38K. The position accounts for ﹤0.01% of the portfolio, ranked #1115.

Belpointe Asset Management first reported a position in NMTC in Q4 2022 and has held it in 3 quarters since. The position peaked at $58.2K in Q1 2026. 26 funds tracked by Wall St. Rank hold NMTC as of Q2 2026.

  • Belpointe Asset Management held 12,500 shares of NeuroOne Medical Technologies worth $38K as of Q2 2026.
  • Belpointe Asset Management left its NeuroOne Medical Technologies share count unchanged in Q2 2026.
  • NeuroOne Medical Technologies made up ﹤0.01% of Belpointe Asset Management's portfolio in Q2 2026, its #1115 holding.
  • Belpointe Asset Management first reported a position in NeuroOne Medical Technologies in Q4 2022 and has held it in 3 quarters since.
  • Belpointe Asset Management's NeuroOne Medical Technologies position peaked at $58.2K in Q1 2026.
  • 26 funds tracked by Wall St. Rank held NeuroOne Medical Technologies as of Q2 2026.

Based on Belpointe Asset Management's 13F filing for Q2 2026, filed 31 Jul 2026.